AI Article Synopsis
- The study explored urinary exosomal mRNA as a potential early biomarker for prostate cancer (PCa), comparing samples from individuals with and without cancer.
- Utilizing next-generation sequencing and further validation with qRT-PCR, researchers identified specific mRNAs, particularly RAB5B and WWP1, that showed promise in distinguishing PCa patients from healthy individuals.
- The combination of RAB5B and WWP1 outperformed traditional PSA tests with a high area under the curve (AUC) value of 0.923, suggesting that this method could significantly enhance early detection of PCa.
Article Abstract
Background: This study investigated the use of urinary exosomal mRNA as a potential biomarker for the early detection of prostate cancer (PCa).
Methods: Next-generation sequencing was utilized to analyze exosomal RNA from 10 individuals with confirmed PCa and 10 individuals without cancer. Subsequent validation through qRT-PCR in a larger sample of 43 PCa patients and 92 healthy controls revealed distinct mRNA signatures associated with PCa.
Results: Notably, mRNAs for RAB5B, WWP1, HIST2H2BF, ZFY, MARK2, PASK, RBM10, and NRSN2 showed promise as diagnostic markers, with AUC values between 0.799 and 0.906 and significance p values. Combining RAB5B and WWP1 in an exoRNA diagnostic model outperformed traditional PSA tests, achieving an AUC of 0.923, 81.4% sensitivity, and 89.1% specificity.
Conclusions: These findings highlight the potential of urinary exosomal mRNA profiling, particularly focusing on RAB5B and WWP1, as a valuable strategy for improving the early detection of PCa.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292860 | PMC |
| http://dx.doi.org/10.1186/s12894-024-01540-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!